These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 19825819)

  • 21. Miltefosine for new world cutaneous leishmaniasis.
    Soto J; Arana BA; Toledo J; Rizzo N; Vega JC; Diaz A; Luz M; Gutierrez P; Arboleda M; Berman JD; Junge K; Engel J; Sindermann H
    Clin Infect Dis; 2004 May; 38(9):1266-72. PubMed ID: 15127339
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined interleukin-12 and topical chemotherapy for established Leishmaniasis drastically reduces tissue parasitism and relapses in susceptible mice.
    Fernandes AP; Carvalho FA; Tavares CA; Santiago HC; Castro GA; Tafuri WL; Ferreira LA; Gazzinelli RT
    J Infect Dis; 2001 Jun; 183(11):1646-52. PubMed ID: 11343214
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of orally administered 2-substituted quinolines in experimental murine cutaneous and visceral leishmaniases.
    Nakayama H; Loiseau PM; Bories C; Torres de Ortiz S; Schinini A; Serna E; Rojas de Arias A; Fakhfakh MA; Franck X; Figadère B; Hocquemiller R; Fournet A
    Antimicrob Agents Chemother; 2005 Dec; 49(12):4950-6. PubMed ID: 16304157
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improved treatment of visceral leishmaniasis (kala-azar) by using combination of ketoconazole, miltefosine with an immunomodulator-Picroliv.
    Shakya N; Sane SA; Vishwakarma P; Bajpai P; Gupta S
    Acta Trop; 2011 Aug; 119(2-3):188-93. PubMed ID: 21679679
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-leishmanial activity of a topical miltefosine gel in experimental models of New World cutaneous leishmaniasis.
    Neira LF; Mantilla JC; Escobar P
    J Antimicrob Chemother; 2019 Jun; 74(6):1634-1641. PubMed ID: 30815688
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the efficacy of systemic miltefosine associated with photodynamic therapy with liposomal chloroaluminium phthalocyanine in the treatment of cutaneous leishmaniasis caused by Leishmania (L.) amazonensis in C57BL/6 mice.
    Ribeiro JBP; Miranda-Vilela AL; Graziani D; Gomes MRA; Amorim AAS; Garcia RD; de Souza Filho J; Tedesco AC; Primo FL; Moreira JR; Lima AV; Sampaio RNR
    Photodiagnosis Photodyn Ther; 2016 Mar; 13():282-290. PubMed ID: 26306406
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination of paromomycin plus human anti-TNF-α antibodies to control the local inflammatory response in BALB/ mice with cutaneous leishmaniasis lesions.
    Schwartz J; Moreno E; Calvo A; Blanco L; Fernández-Rubio C; Sanmartín C; Nguewa P; Irache JM; Larrea E; Espuelas S
    J Dermatol Sci; 2018 Oct; 92(1):78-88. PubMed ID: 30037731
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacological evaluation of anti-leishmanial activity by in vivo nitric oxide modulation in Balb/c mice infected with Leishmania major MRHO/IR/75/ER: an Iranian strain of cutaneous leishmaniasis.
    Nahrevanian H; Farahmand M; Aghighi Z; Assmar M; Amirkhani A
    Exp Parasitol; 2007 Jul; 116(3):233-40. PubMed ID: 17335813
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relapse of new world diffuse cutaneous leishmaniasis caused by Leishmania (Leishmania) mexicana after miltefosine treatment.
    Calvopina M; Gomez EA; Sindermann H; Cooper PJ; Hashiguchi Y
    Am J Trop Med Hyg; 2006 Dec; 75(6):1074-7. PubMed ID: 17172368
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cutaneous leishmaniasis treatment.
    Minodier P; Parola P
    Travel Med Infect Dis; 2007 May; 5(3):150-8. PubMed ID: 17448941
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined treatment of miltefosine and paromomycin delays the onset of experimental drug resistance in Leishmania infantum.
    Hendrickx S; Van den Kerkhof M; Mabille D; Cos P; Delputte P; Maes L; Caljon G
    PLoS Negl Trop Dis; 2017 May; 11(5):e0005620. PubMed ID: 28505185
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of topical liposomes containing meglumine antimoniate (Glucantime) for the treatment of L. major lesion in BALB/c mice.
    Kalat SA; Khamesipour A; Bavarsad N; Fallah M; Khashayarmanesh Z; Feizi E; Neghabi K; Abbasi A; Jaafari MR
    Exp Parasitol; 2014 Aug; 143():5-10. PubMed ID: 24780938
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for New World cutaneous leishmaniasis.
    Armijos RX; Weigel MM; Calvopiña M; Mancheno M; Rodriguez R
    Acta Trop; 2004 Jul; 91(2):153-60. PubMed ID: 15234664
    [TBL] [Abstract][Full Text] [Related]  

  • 34. First case of typical Old World cutaneous leishmaniasis treated with miltefosine.
    Stojkovic M; Junghanss T; Krause E; Davidson RN
    Int J Dermatol; 2007 Apr; 46(4):385-7. PubMed ID: 17442078
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of miltefosine for Bolivian cutaneous leishmaniasis.
    Soto J; Rea J; Balderrama M; Toledo J; Soto P; Valda L; Berman JD
    Am J Trop Med Hyg; 2008 Feb; 78(2):210-1. PubMed ID: 18256415
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Topical paromomycin with or without gentamicin for cutaneous leishmaniasis.
    Ben Salah A; Ben Messaoud N; Guedri E; Zaatour A; Ben Alaya N; Bettaieb J; Gharbi A; Belhadj Hamida N; Boukthir A; Chlif S; Abdelhamid K; El Ahmadi Z; Louzir H; Mokni M; Morizot G; Buffet P; Smith PL; Kopydlowski KM; Kreishman-Deitrick M; Smith KS; Nielsen CJ; Ullman DR; Norwood JA; Thorne GD; McCarthy WF; Adams RC; Rice RM; Tang D; Berman J; Ransom J; Magill AJ; Grogl M
    N Engl J Med; 2013 Feb; 368(6):524-32. PubMed ID: 23388004
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparing the efficiency of topical paromomycin with intralesional meglumine antimoniate for cutaneous leishmaniasis.
    Moosavi Z; Nakhli A; Rassaii S
    Int J Dermatol; 2005 Dec; 44(12):1064-5. PubMed ID: 16409282
    [No Abstract]   [Full Text] [Related]  

  • 38. Comparison between the efficacy of photodynamic therapy and topical paromomycin in the treatment of Old World cutaneous leishmaniasis: a placebo-controlled, randomized clinical trial.
    Asilian A; Davami M
    Clin Exp Dermatol; 2006 Sep; 31(5):634-7. PubMed ID: 16780497
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Leishmania major: activity of tamoxifen against experimental cutaneous leishmaniasis.
    Eissa MM; Amer EI; El Sawy SM
    Exp Parasitol; 2011 Aug; 128(4):382-90. PubMed ID: 21620834
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The putative lipid raft modulator miltefosine displays immunomodulatory action in T-cell dependent dermal inflammation models.
    Bäumer W; Wlaź P; Jennings G; Rundfeldt C
    Eur J Pharmacol; 2010 Feb; 628(1-3):226-32. PubMed ID: 19917276
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.